Reviews/Anti Amyloid Antibodies/Donanemab slows decline in early Alzheimer's disease
Efficacy · AMAB-EFF-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across the studies here, donanemab treated patients with early Alzheimer's disease declined more slowly than those on placebo on standard measures of memory, thinking and daily function. A large phase 3 trial of 1736 people found the drug cut the rate of decline and lowered the chance of progressing to a more advanced stage [1][7], and an earlier, smaller trial of 257 people met its main cognitive-functional target, though only just and with mixed results on secondary measures [5]. Supporting analyses that grouped patients by disease severity or modeled the data all point the same way, toward slower decline [2][11][16], and one independent patient cohort estimated the drug could extend time living independently [17]. The main cautions are that almost all of this evidence comes from the drug maker's own trial program, and that the size of the benefit is small on the scales used. The panel treated the direction of the finding, that decline is slowed, as well supported while noting these limits on magnitude and independence.
Two placebo-controlled randomized trials in early symptomatic Alzheimer's disease reported slower decline with donanemab: a phase 2 trial met its iADRS primary endpoint with a difference of 3.20 (95% CI 0.12 to 6.27, P=0.04) [5], and a phase 3 program in 1736 participants reported the drug 'significantly slowed the rate of clinical decline (by 22-36%)' on iADRS and CDR-SB [7], with risk reductions of 33% for progression from MCI to mild AD and 38% for meaningful CDR-SB change [1]. Subgroup work found slowing across tau PET and plasma P-tau217 strata, greatest with earlier treatment [2]. Pharmacologic and disease-progression modeling across trials 'confirmed that donanemab significantly reduced the rate of clinical decline' [11] and estimated 'around 30% reduction in disease progression rate' [16]. An independent Knight ADRC cohort of 282 participants translated the CDR-SB effect into an estimated 13 months of extended independence in instrumental activities (95% CI 6-24 months) [17]. The contested point: The division is over magnitude and independence rather than direction: the phase 2 effect was small on a 0 to 144 scale with a lower confidence bound near zero and most secondary outcomes showing 'no substantial difference' [5], and much of the quantified slowing comes from post hoc and modeling analyses within a sponsor-dominated program [1][11][16]. The one external cohort reports a modeled projection, not a direct trial outcome [17].
All 23 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti Amyloid Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The phase 2 primary endpoint was only marginally significant (difference 3.20, 95% CI 0.12 to 6.27, P=0.04) with the lower bound nearly at zero, and [5] states results for most secondary outcomes showed no substantial difference — on its own this trial is thin evidence.
Evidential independence is weak: almost all efficacy evidence derives from the Eli Lilly-sponsored TRAILBLAZER program and Lilly-authored analyses ([1][2][7][11][16]); only the Knight ADRC cohort [17] is external, and it reports a modeled projection rather than a direct trial outcome.
Where it remains uncertain. The supporting phase 2 trial met its primary endpoint only marginally (difference 3.20; 95% CI 0.12 to 6.27; P=0.04) with mixed secondaries [5], and nearly all evidence derives from the Eli Lilly TRAILBLAZER program and Lilly-authored analyses [1][2][7][11][16].
Aleatory
Observed cognitive change varies substantially between treated individuals, so a group-level slowing need not predict any one patient's course [13].
The load-bearing papers from a corpus of 23, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Phase 3 trial shows robust, highly significant reductions in meaningful clinical progression.
“donanemab reduced MWPC risk over 76 weeks by 38% for CDR-SB (HR = 0.62; 95% CI 0.52-0.75; p < 0.001) and 30% for iADRS (HR = 0.70; 95% CI 0.58-0.84; p < 0.001).”
Panel auditInternal validity: high · scope of inference: People with MCI or mild AD-related dementia in TRAILBLAZER-ALZ 2.Key limitations: includes post hoc analyses · N not stated in abstract · industry trial
Demonstrates the slowing effect is not confined to a single pathology stratum.
“Donanemab-mediated slowing of disease progression occurred across baseline tau PET and plasma P-tau217 levels.”
Panel auditInternal validity: high · scope of inference: Early symptomatic AD across clinical and pathological severity strata in TRAILBLAZER-ALZ 2.Key limitations: no p-values or CIs in abstract · subgroup/modeling analysis · N not stated
Prespecified phase 2 primary endpoint met, establishing a statistically significant slowing of combined cognitive-functional decline.
“The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04).”
Panel auditInternal validity: high · scope of inference: Early symptomatic AD with amyloid and tau deposition on PET.Key limitations: secondary outcomes mostly no difference · small sample · longer/larger trials called for by authors
Independent modeling of primary data corroborates reduced decline rate.
“The disease-progression models confirmed that donanemab significantly reduced the rate of clinical decline.”
Panel auditInternal validity: medium · scope of inference: Donanemab exposure-response in AD participants from phase 1 and TRAILBLAZER-ALZ.Key limitations: modeling/pharmacometric analysis · no raw endpoint CIs in abstract · model assumptions
4 of 23 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Two positive placebo-controlled RCTs with met prespecified endpoints and uniformly concordant supporting analyses establish that donanemab slows clinical decline, with confidence held just inside the Established band to reflect heavy sponsor dependence and modest effect sizes.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent confirmatory trial. Almost all efficacy evidence here is sponsor-generated [1][2][7][11][16], so the direction of effect has no non-sponsor randomized replication in this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A publicly or independently funded placebo-controlled RCT in early symptomatic AD using the same prespecified cognitive-functional endpoints.
Open question: Does donanemab slow decline when tested outside the sponsor's trial program? Why it is still open: The corpus's only external evidence is a modeled cohort projection [17]; every randomized efficacy result is from the Lilly TRAILBLAZER program [1][2][7][11][16].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19